<?xml version="1.0" encoding="UTF-8"?>
<p>In simplified terms benefit risk analysis is performed to answer the questionâ€”do the benefits of a NBM outweigh the risks to the target individual or population and are the uncertainties reasonably low [
 <xref rid="B121-materials-13-04532" ref-type="bibr">121</xref>]? The answer to this question is important for both the industry developing these NBMs and the regulatory authorities. Benefit risk analysis is generally performed when applying for market approval for a medicine following clinical trials, however it has been recognised that the approach should be performed throughout the whole R&amp;D phases of the medicinal product, including the non-clinical discovery phase, the clinical phases (phase I, II, III) and the post-marketing pharmacovigilance [
 <xref rid="B19-materials-13-04532" ref-type="bibr">19</xref>,
 <xref rid="B20-materials-13-04532" ref-type="bibr">20</xref>]. 
</p>
